Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on November 21, 2025, regarding a Special Meeting of stockholders held by Xilio Therapeutics, Inc., a Delaware corporation. The company is an emerging growth company listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance actions and equity compensation adjustments.
Material Changes and Corporate Actions
At the Special Meeting, stockholders approved two primary proposals:
- 2025 Stock Incentive Plan: Approval of a new equity incentive plan to replace or supplement existing plans.
- Option Repricing: A one-time repricing of certain outstanding employee stock options. The exercise price for these options was reduced to $1.50 per share.
Repricing Details for Executive Officers:
| Name and Position | Shares Subject to Options | Original Weighted-Avg Exercise Price | New Exercise Price |
|---|---|---|---|
| René Russo, Pharm.D. (CEO) | 2,198,212 | $5.76 | $1.50 |
| Christopher Frankenfield (CFO/COO) | 848,172 | $4.67 | $1.50 |
| Katarina Luptakova, M.D. (CMO) | 225,210 | $4.10 | $1.50 |
Voting Results:
- Proposal 1 (Repricing): 31,600,793 For; 1,690,846 Against; 144,025 Abstaining.
- Proposal 2 (2025 Plan): 30,542,811 For; 2,876,155 Against; 16,698 Abstaining.
- Proposal 3 (Adjournment): 30,757,060 For; 2,635,979 Against; 42,625 Abstaining.
Guidance, Risks, and Unusual Items
Repricing Restrictions: If a repriced option is exercised prior to the 12-month anniversary of the repricing date (November 21, 2026), the holder must pay the original exercise price, not the reduced price. Exceptions apply only in cases of death, disability, or a change in control.
Management Commentary: The filing does not contain forward-looking guidance or management commentary regarding financial performance or clinical pipeline updates.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the newly approved 2025 Stock Incentive Plan (details in the referenced DEF 14A).
- Confirm the total dilution impact of the repriced options across the entire employee base, not just the named executives.
- Review the "Original Exercise Price" restriction clause to understand the effective value of the options for employees exercising them within the next 12 months.
- Check subsequent filings for any changes in the company's cash burn rate or funding status, as this filing does not disclose liquidity.